ArQule Added to the NASDAQ Biotechnology Index
The Index is designed to track the performance of a set of securities
“Inclusion in the NBI reflects ArQule’s clinical progress and heightened
investor awareness throughout 2018,” said
Forward Looking Statements
This press release contains forward-looking statements regarding our clinical programs, including a statement regarding our focus on their rapid advancement and future data inflection points. These statements are based on the Company's current beliefs and expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Positive information about early clinical results does not ensure that later-stage clinical trials will be successful. For example, our drug candidates may not demonstrate promising therapeutic effect in man; in addition, they may not exhibit an adequate safety profile in planned or later stage or larger scale clinical trials as a result of known or as yet unanticipated side effects. The results achieved in later stage trials may not be sufficient to meet applicable regulatory standards or to justify further development. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing our drug candidates that could lead the Company to discontinue development. Even if later stage clinical trials are successful, unexpected concerns may arise from subsequent analysis of data or from additional data. Obstacles may arise or issues may be identified in connection with review of clinical data with regulatory authorities. Regulatory authorities may disagree with the Company's view of the data or require additional data or information or additional studies. In addition, we are utilizing diagnostic tests to identify patients in a number of trials and expect to utilize diagnostic tests in other clinical trials. We or our collaborators may need to develop and register these or other diagnostic tests as companion diagnostics with the FDA. We or our collaborators may encounter difficulties in developing and obtaining regulatory approval for companion diagnostics, including issues relating to access to certain technologies, selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators or us to develop or obtain regulatory approval of companion diagnostics could delay or prevent approval of our product candidates. Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. For more detailed information on the risks and uncertainties associated with the Company's drug development and other activities, see the Company's periodic reports filed with the
Marc Schegerin, M.D.
Senior Vice President
Head of Strategy, Finance and Communication
Allison Blum, Ph.D.
LifeSci Public Relations (646) 627-8383